Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Rob Wills
AddedFeb 19, 2024
UpdatedMay 31, 2026
Rob Wills

Rob Wills

Board Member, CymaBay Therapeutics

CrunchbaseLinkedIn

Rob Wills's Career

CymaBay Therapeutics
CymaBay Therapeutics

Newark, CA, US

Board Member· Board
GO Therapeutics
GO Therapeutics

Cambridge, MA, US

Board Member· Board
Parion Sciences
Parion Sciences

Durham, NC, US

Board Member· Board
Oncternal Therapeutics
Oncternal Therapeutics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Rob Wills's Career

CymaBay Therapeutics
CymaBay Therapeutics
Acquired$710.2M01991Newark, CA, US
Board Member· Board

Leadership at CymaBay Therapeutics

Kurt von EmsterKurt von EmsterBoard Member
Janet DorlingJanet DorlingBoard Member
Sujal A ShahSujal A ShahCo-Founder
Eric LefebvreEric LefebvreBoard Member
Caroline LoewyCaroline LoewyBoard Member
Tom WiggansTom WiggansBoard Member

Similar to CymaBay Therapeutics

Bluejay TherapeuticsBluejay TherapeuticsSan Francisco, CA, USDrugs, Therapeuticsest. 2019Bluejay TherapeuticsSan Francisco, CA, US · est. 2019

Bluejay Therapeutics: A private biopharma firm developing innovative cures for infectious diseases.

Series B · $41M14
Cyclo TherapeuticsCyclo TherapeuticsGainesville, FL, USBiotech, Treatmentsest. 1990Cyclo TherapeuticsGainesville, FL, US · est. 1990

Cyclo Therapeutics: A US-based clinical-stage biotech firm developing treatments for unmet medical needs.

Public · $16.8M9
NGM BiopharmaceuticalsNGM BiopharmaceuticalsSouth San Francisco, CA, USTherapeuticsest. 2007NGM BiopharmaceuticalsSouth San Francisco, CA, US · est. 2007

NGM Biopharmaceuticals: A clinical-stage company developing novel therapeutics for various diseases in the US.

Public · $420.4M225
Nimbus TherapeuticsNimbus TherapeuticsCambridge, MA, USDrugs, Therapeuticsest. 2009Nimbus TherapeuticsCambridge, MA, US · est. 2009

Nimbus Discovery: A US-based clinical-stage biotech firm specializing in metabolic, oncology, and immune-inflammatory treatments.

Public · $637M112
GO Therapeutics
GO Therapeutics
Series A$5M112014Cambridge, MA, US
Board Member· Board

Leadership at GO Therapeutics

Mr. Constantine TheodoropulosMr. Constantine TheodoropulosCo-Founder
Henrik ClausenHenrik ClausenCo-Founder
Sam MurphySam MurphyBoard Member
Hans WandallHans WandallCo-Founder
Vikas SharmaVikas SharmaBoard Member

Similar to GO Therapeutics

G1 TherapeuticsG1 TherapeuticsTriangle (historical), NC, USCancer Therapiesest. 2008G1 TherapeuticsTriangle (historical), NC, US · est. 2008

US-based G1 Therapeutics develops innovative treatments for oncology and breast cancer.

Public · $697.4M170
Geneos TherapeuticsGeneos TherapeuticsPlymouth Meeting, PA, USCancer Treatmentest. 2016Geneos TherapeuticsPlymouth Meeting, PA, US · est. 2016

Geneos Therapeutics: Pioneering personalized immunotherapy for effective cancer treatment.

Series A · $49.5M30
Tango TherapeuticsTango TherapeuticsBoston, MA, USCancer Therapiesest. 2017Tango TherapeuticsBoston, MA, US · est. 2017

Tango Therapeutics: A US-based biotech firm innovating transformative cancer therapies.

Public · $351M110
Checkpoint TherapeuticsCheckpoint TherapeuticsWaltham, MA, USCancer Therapiesest. 2014Checkpoint TherapeuticsWaltham, MA, US · est. 2014

Checkpoint Therapeutics: A clinical-stage biopharmaceutical company focused on cancer therapy development.

Public · $10M24
Parion Sciences
Parion Sciences
Seed$3M101999Durham, NC, US
Board Member· Board

Leadership at Parion Sciences

Paul BoucherPaul BoucherCEO
Ross JohnsonRoss JohnsonBoard Member

Similar to Parion Sciences

PulmatrixPulmatrixLexington, MA, USTherapeuticsest. 2003PulmatrixLexington, MA, US · est. 2003

Pulmatrix, Inc.: A US-based biotech firm specializing in therapies for chronic respiratory diseases.

Public · $148.4M24
Paratus SciencesParatus SciencesNew York City, NY, USHealth Solutions, Therapeuticsest. 2021Paratus SciencesNew York City, NY, US · est. 2021

Paratus Sciences: A biotech start-up leveraging bat biology for innovative human health solutions.

Series A · $100M38
PulmokinePulmokineRensselaer, NY, USTherapiesest. 2007PulmokineRensselaer, NY, US · est. 2007

Pulmokine: A private biopharmaceutical firm based in Rensselaer, US.

Pre-Seed · $1M75
Inception SciencesInception SciencesSan Diego, CA, USPharmaceuticalsest. 2011Inception SciencesSan Diego, CA, US · est. 2011

Inception Sciences: Developing and marketing high-value pharmaceutical therapies for chronic diseases in the US.

Series A · $20M30
Oncternal Therapeutics
Oncternal Therapeutics
Public$132M302013San Diego, CA, US
Board Member· Board

Leadership at Oncternal Therapeutics

Lauren OtsukiLauren OtsukiFounder
Michael G. CarterMichael G. CarterBoard Member
William R. LaRueWilliam R. LaRueBoard Member
Daniel KisnerDaniel KisnerBoard Member
Cam GallagherCam GallagherBoard Member
David F. HaleDavid F. HaleBoard Member

Rob Wills's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Rob Wills

Neal Ira GoldmanNeal Ira GoldmanBoard Member · Milestone ScientificWilliam D. WaddillWilliam D. WaddillBoard Member · Arrowhead PharmaceuticalsMichael PelliniMichael PelliniBoard Member · Foundation MedicinePeter SvennilsonPeter SvennilsonFounder · The Column GroupRuss RayRuss RayBoard Member · PhreesiaTim WollaegerTim WollaegerCo-Founder · Fresh Tracks Therapeutics